TTR and prealbumin measurement: The first marketed RNAi therapeutic, approved in 2018, is Patisiran (Onpattro, Alnylam), administered for the rare misfolding disorder hereditary transthyretin (TTR) amyloidosis [86], where liver-derived amyloidic mutant TTR protein leads to multi-organ dysfunction.